Orphan Drugs Market Global Report 2020-30 from the author provides the strategists, marketers and senior management with the critical information they need to assess the global orphan drugs market.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the orphan drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Orphan Drugs market global report from the author answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider orphan drugs market, and compares it with other markets.
Scope
Markets Covered: 1) By Therapy Area: Oncology; Blood; Central Nervous System; Endocrine; Cardiovascular; Respiratory; Immunomodulatory; 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Sales
Companies Mentioned: Bristol-Myers Squibb Company; Celgene Corporation; F. Hoffmann-La Roche Ltd; Amgen; Biogen
Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3 working days of order.
Description:
Where is the largest and fastest growing market for the orphan drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Orphan Drugs market global report from the author answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider orphan drugs market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
- The orphan drugs market section of the report gives context. It compares the orphan drugs market with other segments of the orphan drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, orphan drugs indicators comparison.
Scope
Markets Covered: 1) By Therapy Area: Oncology; Blood; Central Nervous System; Endocrine; Cardiovascular; Respiratory; Immunomodulatory; 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Sales
Companies Mentioned: Bristol-Myers Squibb Company; Celgene Corporation; F. Hoffmann-La Roche Ltd; Amgen; Biogen
Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1. Executive Summary2. Orphan Drugs Market Characteristics26. Key Mergers And Acquisitions In The Orphan Drugs Market27. Orphan Drugs Market Trends And Strategies28. Orphan Drugs Market Future Outlook and Potential Analysis
3. Orphan Drugs Market Size And Growth
4. Orphan Drugs Market Segmentation
5. Orphan Drugs Market Regional And Country Analysis
6. Asia-Pacific Orphan Drugs Market
7. China Orphan Drugs Market
8. India Orphan Drugs Market
9. Japan Orphan Drugs Market
10. Australia Orphan Drugs Market
11. Indonesia Orphan Drugs Market
12. South Korea Orphan Drugs Market
13. Western Europe Orphan Drugs Market
14. UK Orphan Drugs Market
15. Germany Orphan Drugs Market
16. France Orphan Drugs Market
17. Eastern Europe Orphan Drugs Market
18. Russia Orphan Drugs Market
19. North America Orphan Drugs Market
20. USA Orphan Drugs Market
21. South America Orphan Drugs Market
22. Brazil Orphan Drugs Market
23. Middle East Orphan Drugs Market
24. Africa Orphan Drugs Market
25. Orphan Drugs Market Competitive Landscape And Company Profiles
29. Appendix
Executive Summary
The orphan drugs market consists of sales of orphan drugs and related services that are used to treat rare diseases. An orphan drug is a pharmaceutical drug developed to treat patients suffering from rare diseases and would not make profit if developed commercially.The global orphan drugs market was worth $132.61 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 7.86% and reach $179.49 billion by 2023.
The orphan drugs market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa. North America was the largest region during the period 2015-2023
The orphan drugs market covered in this report are segmented by therapy area into oncology, blood, central nervous system, endocrine, cardiovascular, respiratory, immunomodulatory. They are also segmented by distribution channel into hospital pharmacy, retail pharmacy, and online sales.
The rising prevalence of rare diseases is a key factor driving the growth of the orphan drugs market. Any disease that affects a small percentage of the population is a rare disease. Rare disease treatments often require a cold chain, a supply chain regulated by temperature that is not readily accessible in all countries. Orphan diseases or rare diseases occurs rarely among the people (i.e. 7 out of 10,000). However, globally, the prevalence of rare diseases is increasing in recent years. In 2017, there were 7,000 identified rare diseases, including hemophilia, Gaucher disease, Hunter syndrome and many types of rare cancer. Some cases of aplastic anemia, caused by damage to stem cells in the bone marrow that are diagnosed in around 500 to 1,000 individuals in the USA each year, are inherited. Thus, the rising prevalence of rare diseases is driving the growth of the orphan drugs market.
Lack of supportive government policies hinders the orphan drugs market. Due to the lack of relevant policies for orphan drug, certain drugs do not receive any special recognition or priorities for approval by regulatory authority. Medgenome Labs Ltd., global research partner in accelerating insights into complex genetic diseases, pointed out that companies manufacturing orphan drugs frequently drop out in foreign markets due to a lack of government funding. For example, orphan medical products (OMPs) in India, due to lack of proper regulations and clear guidelines, do not obtain tax cuts or exemptions from customs duties. Therefore, lack of supportive government policies limits the growth of the orphan drugs market.
Approval of biological orphan drugs for multiple indication act as a key trend driving the growth of the orphan drugs market. The biological drugs are used for treating rare diseases such as cancer with fewer side effects that have a high prevalence rate in the developed world. For Instance, in 2018, in order to launch the company’s biological orphan drug development program Cardax, Inc. announced that it has been engaged with biological orphan drug expert Frederick D. Sancilio, Ph.D. For the development of commercial products, the companies are focused on obtaining biological orphan drugs to increase their revenue.
In November 2019, Bristol-Myers Squibb, a biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines, acquired Celgene for an undisclosed amount. Through this acquisition, Celgene shareholders received for each share, 1 share of Bristol-Myers Squibb common stock, $50.00 in cash without interest and one tradeable Contingent Value Right (CVR), which will entitle the holder to receive a payment of $9.00 in cash if certain future regulatory milestones are achieved. Celgene, a biopharmaceutical company positioned to address the needs of the patients with serious diseases.
Major players in the market are Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd, Amgen, Biogen, Bayer, Novartis AG, GlaxoSmithKline plc, Johnson & Johnson and AbbVie Inc.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bristol-Myers Squibb Company
- Celgene Corporation
- F. Hoffmann-La Roche Ltd
- Amgen
- Biogen
- Bayer
- Novartis AG
- GlaxoSmithKline plc
- Johnson & Johnson
- AbbVie Inc
- Eli Lilly and Company
- Alexion Pharmaceuticals
- Shire
- Novo Nordisk
- AstraZeneca
- Eisai
- Daiichi Sankyo
- Merck
- Teva Pharmaceutical Industries
- Actelion Pharmaceuticals Ltd.
- Aegerion Pharmaceuticals
Methodology
LOADING...
